...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019

I don't want to throw anything on the party but I will be much more cautious in my interpretation of the statement.

"Among other findings, the Company will highlight that Apabetalone treatment illustrated statistically significant improvements compared to top standard of care placebo in cardiovascular disease patients with moderate to severe cognitive decline."

I think they are just saying there is a cardio improvement (less MACE) maybe within this sub-group. I still feel that saying there is statistically significant improvement in cognition an hour ago would be infringing on the embargo. I will wait a little longer.

Share
New Message
Please login to post a reply